Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Your view on REGN
Overview
What the company does, where it operates, and who runs it.
About Regeneron Pharmaceuticals, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Leonard S. Schleifer
- Headquarters
- 777 Old Saw Mill River Road, Tarrytown, NY, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Leonard S. Schleifer
- Headquarters
- 777 Old Saw Mill River Road, Tarrytown, NY, US
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.
In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions.
It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC.
The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Regeneron Pharmaceuticals, Inc. from FRC's valuation model, read against the market price. REGN last traded at $952.40, 20.2× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Regeneron Pharmaceuticals, Inc.. Starting points for Regeneron Pharmaceuticals, Inc.: P/E 20.2, EPS $47.37, beta 0.24 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Regeneron Pharmaceuticals, Inc.. Regeneron Pharmaceuticals, Inc. paid $3.70 per share over the last year — a 0.4% yield at the current $952.40 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Regeneron Pharmaceuticals, Inc.. Trailing twelve-month EPS for Regeneron Pharmaceuticals, Inc. stands at $47.37. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$899.32
average of 25 firms, last 12 months
Analyst Ratings
- Strong Buy0
- Buy17
- Hold8
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $25.80 | $15.94 | $68.23 | $70.90 |
| Low estimate | $15.83 | $14.79 | $54.98 | $60.66 |
| High estimate | $31.72 | $16.60 | $75.39 | $78.21 |
| No. of analysts | 14 | 6 | 15 | 10 |
| Year-ago EPS | $11.44 | $9.47 | $41.481 | — |
| Growth | +125.5% | +68.3% | — | — |
1Year-ago EPS includes one-time items; growth not shown.
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $5.85B | $4.60B | $18.78B | $20.15B |
| Low estimate | $4.56B | $4.41B | $16.48B | $17.76B |
| High estimate | $6.28B | $4.82B | $19.88B | $21.60B |
| No. of analysts | 12 | 5 | 19 | 19 |
| Year-ago revenue | $3.88B | $3.61B | $14.34B | — |
| Growth | +50.7% | +27.7% | +30.9% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0; as of Nov 18, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Regeneron Pharmaceuticals, Inc.. Regeneron Pharmaceuticals, Inc. has reported as a listed company since 1991. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- AMGNAmgen Inc.Drug Manufacturers - General$250.1B
- AZNAstraZeneca PLCDrug Manufacturers - General$285.4B
- BIIBBiogen Inc.Drug Manufacturers - General$37.2B
- EYPTEyePoint Pharmaceuticals, Inc.Biotechnology$26M
- GILDGilead Sciences, Inc.Drug Manufacturers - General$207.9B
- GMABGenmab A/SBiotechnology$31.8B
- IVBXFInnovent Biologics, Inc.Biotechnology$19.4B
- NVSNovartis AGDrug Manufacturers - General$302.6B
More Biotechnology companies
- RNAZTransCode Therapeutics, Inc.NASDAQ$1M
- RNTXRein Therapeutics Inc.NASDAQ$35M
- RNUGFReNeuron Group plcOTC$62,891
- RNXTRenovoRx, Inc.NASDAQ$46M
- ROIVRoivant Sciences Ltd.NASDAQ$28.0B
- RVLPQRVL Pharmaceuticals plcOTC$1,114
- RVMDRevolution Medicines, Inc.NASDAQ$36.1B
- RVMDWRevolution Medicines, Inc. WarrantNASDAQ$34.1B
- RVPHReviva Pharmaceuticals Holdings, Inc.OTC$36M
- RVX.TOResverlogix Corp.TSX$26M
- RVXCFResverlogix Corp.OTC$23M
- RXRXRecursion Pharmaceuticals, Inc.NASDAQ$1.8B
ETFs holding Regeneron Pharmaceuticals, Inc.
% of the fund
- VOOVanguard S&P 500 ETF$1.0T in assets0.14%
- VTIVanguard Total Stock Market ETF$689.2B in assets0.13%
- QQQInvesco QQQ Trust, Series 1$446.1B in assets0.46%
- IVViShares Core SP 500 ETF$852.9B in assets0.15%
- BBHVanEck Biotech ETF$536M in assets8.08%
- PBEInvesco Biotechnology & Genome ETF$438M in assets5.92%
- HHL.TOHarvest Healthcare Leaders Income ETF$2.2B in assets5.41%
- FBTFirst Trust NYSE Arca Biotechnology Index Fund$3.0B in assets4.26%
Largest holders first, then the funds most concentrated in REGN.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Regeneron Pharmaceuticals, Inc., and how their positions are changing. At a $98.51B market value, institutional positions materially move Regeneron Pharmaceuticals, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Regeneron Pharmaceuticals, Inc. executives and directors. Shares of Regeneron Pharmaceuticals, Inc. have traded between $476.49 and $800.99 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
About this section
U.S. Senate disclosures naming Regeneron Pharmaceuticals, Inc.. Regeneron Pharmaceuticals, Inc. is a $98.51B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
About this section
U.S. House of Representatives disclosures naming Regeneron Pharmaceuticals, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Regeneron Pharmaceuticals, Inc.. Coverage tracks Regeneron Pharmaceuticals, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Regeneron Pharmaceuticals, Inc.